At AMILI, we're partnering with UK-based Sequential Skin Ltd (SSL), leaders in skin microbiome testing, to pioneer a next-generation microbiome kit. Unlike traditional tests, this kit will analyze gut, skin, and oral microbiomes together, revealing how these ecosystems interact.

Using advanced sequencing, we're identifying microbial markers tied to inflammatory skin disorders (ISDs) like eczema. Backed by a $1.8M UK-Singapore Collaborative R&D Grant from Innovate UK and Enterprise Singapore, Project Scratch aims to create an at-home, non-invasive kit that delivers precise, actionable insights for personalized skin health.

Why is this research important?

Inflammatory skin disorders affect 20-25% of people worldwide, yet diagnostics overlook gut-skin-oral interactions that drive immunity and inflammation. By mapping these microbial networks across body sites, this project could transform prevention and care, providing deeper insights into skin health and personalized recommendations for better skincare.

What does participation involve?

AMILI and Sequential Skin Ltd are recruiting 600 participants (300 healthy adults and 300 with mild-to-moderate eczema) for a simple observational study:

• Provide non-invasive samples (stool, skin swabs, saliva) via at-home collection kits.
• Fill out short questionnaires on medical history, diet, and lifestyle.
• Contribute to building the first cross-body microbiome database—no clinic visits required.
  
  

Complete the pre-screener now to check your eligibility for the study: https://tinyurl.com/ProjectScratch2026